Effectiveness of seasonal mRNA COVID-19 vaccination against post COVID-19 condition between July 2023 and September 2024 among adults aged ≥ 60 years in Germany: a population-based cohort study
Nita Perumal, Caroline Peine, Annika Steffen, Ole Wichmann, Thomas Harder · 2026
Read Effectiveness of seasonal mRNA COVID-19 vaccination against post COVID-19 condition between July 2023 and September 2024 among adults aged ≥ 60 years in Germany: a population-based cohort study by Nita Perumal, Caroline Peine, Annika Steffen, Ole Wichmann, Thomas Harder (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13264817.txt.
Description
Nita Perumal and colleagues published a 2026 cohort study from Germany on whether a seasonal mRNA COVID-19 vaccine dose guards against post COVID-19 condition, the long-lasting symptoms some people keep after infection. Older estimates came from the pandemic years, so post-pandemic data were needed. The study covered adults aged 60 and over.
Using nationwide outpatient claims, the team followed more than 19 million people in the 2023 to 2024 season. About 18 percent took one dose, and 0.2 percent overall met the long COVID case rule. The rate was 0.08 percent in vaccinated people against 0.22 percent in others. After adjustment, one dose linked to 63 percent lower risk over six months. The authors say the result supports vaccination choices for older adults.
Catalog record
| CREATOR | Nita Perumal, Caroline Peine, Annika Steffen, Ole Wichmann, Thomas Harder |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29357 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |